PNC Financial Services Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

PNC Financial Services Group’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,691	Closed	-$396K	–	4872
2023 Q1	$396K	Buy	3,691 +2,269	+160%	+$261K	﹤0.01%	1694
2022 Q4	$156K	Buy	1,422 +1,220	+604%	+$79.1K	﹤0.01%	2288
2022 Q3	$12K	Buy	202 +104	+106%	+$4.76K	﹤0.01%	3695
2022 Q2	$3K	Buy	+98	New	+$2.84K	﹤0.01%	4149

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

PNC Financial Services Group's RXDX Position: Q2 2023 in Review

PNC Financial Services Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 3,691 shares — an estimated $396K sold.

PNC Financial Services Group first reported a position in RXDX in Q2 2022 and held it in 4 quarters. The position peaked at $396K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

PNC Financial Services Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
PNC Financial Services Group sold 3,691 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $396K.
PNC Financial Services Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
PNC Financial Services Group's Prometheus Biosciences, Inc. Common Stock position peaked at $396K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on PNC Financial Services Group's 13F filing for Q2 2023, filed 11 Aug 2023.